 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- | Journal, IO biomarker: CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vδ2 T cell cytotoxicity. (Pubmed Central) - Sep 14, 2022
These findings suggest a decisive role of CD277 in mediating the recognition of R/R AML cells by Vδ2 T cells. CD277 agonist combining adoptive transfer of Vδ2 T cells may improve the efficacy in the treatment of R/R AML.